Role of Oral Zinc Supplementation in treatment of Acute Dehydrating Diarrhea in age 6 months to 5 years

2021 ◽  
Vol 15 (11) ◽  
pp. 3002-3003
Author(s):  
Bakht Buland Shah ◽  
Inam ul Khair
Keyword(s):  
Placebo Group ◽  
Zinc Supplementation ◽  
Oral Rehydration Salt ◽  
Course Of Disease ◽  
Oral Rehydration ◽  
Oral Supplementation ◽  
Recommended Treatment ◽  
Double Blinded ◽  
Volume Current

Background: Oral Rehydration Salt (ORS) is the standard recommended treatment for acute dehydrating diarrhea but it has very little role in decreasing stool frequency and volume. Current studies recommend oral supplementation of zinc as an adjunct to ORS in treating acute dehydrating diarrhea of children especially those who are at risk of zinc deficiency and malnutrition. Aim: To determine the effect of oral zinc supplementation on duration of acute diarrhea and intake of ORS in children between 6 months and 5 years of age. Settings: Tehsil Head Quarters Hospital, Besham District Shangla, Khyber Pakhtunkhwa from October 2019 to September 2020. Methodology: The study was double blinded Randomized Control Clinical Trial in children aged between 6 months to 5 years of age. A total of 90 children were included in the study. In addition to rehydration, 45 children were given oral zinc (20mg daily) while 45 children were given placebo. Results: All 45(100%) patients in zinc group and 39(86.6%) patients in placebo group recovered after 5 days of treatment. Zinc group had significantly reduced duration of diarrhea (68.3±9.4 vs. 99.8±15.2 hours) and consumed less ORS solution (2.3±0.8 vs. 3.4±1.1 liters) as compared to placebo group. Conclusion: It is concluded from this study that oral zinc supplementation in addition to ORS in treating acute dehydrating diarrhea of children has better effect on the clinical course of disease. Key words: Diarrhea, ORS, Zinc, Dehydration.

Awareness of quantity of ORS and Zinc among mothers of under five children with diarrhoea at a tertiary care Centre Lahore

2021 ◽  
pp. 1-10
Author(s):  
Mubeen Nazar Duggal ◽  
Attia Bari ◽  
Ayesha Mansoor ◽  
Sara Saeed ◽  
Wajiha Rizwan ◽  
...  
Keyword(s):  
Tertiary Care ◽  
Cross Sectional Study ◽  
Oral Rehydration Salt ◽  
Tertiary Care Centre ◽  
Cross Sectional ◽  
Oral Rehydration ◽  
Under Five ◽  
Under Five Children ◽  
Number Of Children

Abstract Objectives: To assess mothers’ knowledge about quantity of ORS and zinc in management of diarrhoea. Methods: Cross sectional study conducted over a period of 4 months from May 2019 to August 2019 among mothers accompanying under five children admitted in the diarrhoea ward of The Children’s hospital Lahore for rehydration and included 334 children age 2 months to 59 months. Data was collected regarding age, sex, residence, number of children in house hold, socioeconomic status, maternal literacy status, mother’s awareness of signs of dehydration in diarrhoea, familiarity with the term oral rehydration salt (ORS) as regards its correct preparation and administration and Zinc supplementation in diarrhoea. Conclusion: Majority mothers were aware of ORS and doctors were the main source of information. Many knew the correct role of ORS in diarrhoea and its method of preparation as sachet pack was the most commonly used type. Although ORS use rate was high, but most mothers were unaware of quantity of ORS to be given. Zinc use in diarrhoea was very low in our study. Keywords: Awareness, ORS, Zinc, Diarrhoea.

Randomized Placebo-Controlled Clinical Study on the Role of Zinc in Low Birth Weight Neonates

2014 ◽  
Vol 7 (2) ◽  
pp. 2423-2428
Author(s):  
Ch. Laxman Kumar ◽  
D. Sai Chandar ◽  
Narendar D ◽  
Shireesha V
Keyword(s):  
Placebo Group ◽  
Weight Gain ◽  
Birth Weight ◽  
Low Birth Weight ◽  
Zinc Supplementation ◽  
Postnatal Growth ◽  
Mortality And Morbidity ◽  
Significant Length ◽  
Randomized Controlled Trail

Low birth weight (LBW) is one of the important causes of neonatal mortality and morbidity in developing countries. It is hypothesized that LBW neonates are zinc deficient and that might adversely affect postnatal growth. The objective of the investigation was to compare the effect of oral zinc supplementation on growth of low birth weight neonates by randomized controlled trail. 100 LBW neonates between 1501-2499 gm were randomized into zinc and placebo groups. We supplemented zinc 10 mg/day to zinc group and multivitamin drops to placebo group for 28 days. Measure the weight and length according to study schedule. Primary outcome was increment in weight and length and data were analyzed by SPSS. The mean birth weight was 1850 ± 302 gm and 1813 ± 271 gm for zinc and placebo groups, respectively. After 28 days 2595 ± 503 gm with mean weight gain of 26 ± 11 gm/day in zinc group and 2322 ± 472 gm with mean weight gain of 18 ± 9.4 gm/day in placebo group, which was statistically significant (p < 0.001). There was significant length gain (p < 0.001) in zinc group compare to placebo group. Zinc group experienced remarkably less problems like sepsis, duration of hospital stay and jaundice. There were no adverse effects noted in zinc group. Zinc supplementation for LBW neonates was found effective to enhance growth in neonatal period.  

Role of Racecadotril in Children with Acute Diarrhea

2021 ◽  
Vol 36 (1) ◽  
pp. 8-13
Author(s):  
Azmeri Sultana ◽  
Parijat Bishwas ◽  
Shahidul Islam ◽  
Uzzal Kumar Ghosh ◽  
Kazi Iman ◽  
...  
Keyword(s):  
Placebo Group ◽  
Acute Diarrhea ◽  
Watery Diarrhea ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Safe Treatment ◽  
Oral Rehydration ◽  
Acute Watery Diarrhea ◽  
Adults And Children

Background: Diarrhea is a leading cause of illness and death among children in developing countries. Racecadotril (acetorphan), an enkephalinase inhibitor with antisecretory and anti-diarrheal actions, is an effective and safe treatment for acute diarrhea in adults and children. Objectives: The objective of this study is to evaluate the efficacy and tolerability of racecadotril as a treatment of acute diarrhea in children. Methods: This double-blind, randomized controlled clinical trial was conducted in Dr. MR Khan Children Hospital & Institute of Child Health over 1 year (June 2017- May 2018). The study was approved by the ethical committee of the institute. The efficacy and tolerability of racecadotril (1.5 mg/kg) administered orally 3 times daily) as adjuvant therapy to oral rehydration or intravenous fluid were compared with those of placebo in 40 children aged 3 months to 60 months of children who had acute diarrhea. Results: During the first 72 hours of treatment, patients receiving racecadotril had a significantly lower stool output (grams per hour) than those receiving placebo. The mean (±SE) 72-hours stool output was 54.75± 12.92 g per kilogram in the racecadotril group and 152.50±37.64 g per kilogram in the placebo group (p<0.001). The number of purging is significantly reduced in the racecadotril group than the placebo group (11.95±2.41 Vs 14.85±1.95, p= 0.000) on third day of admission. The duration of hospital stay is significantly lower in the racecadotril group than the placebo group (73.30±23.44 vs. 177.30±25.8. p= 0.000) group. Racecadotril was well tolerated; only 3 patients taking racecadotril had adverse effects like vomiting and 2 patients had hypokalaemia and 3 patients in the placebo group developed vomiting and 1patient developed hypokalaemia which all are mild and transient. Conclusion: In young children with acute watery diarrhea, racecadotril is an effective and safe treatment along with rehydration therapy. DS (Child) H J 2020; 36(1) : 8-13

scholarly journals Zinc Supplementation and Recurrent Diarrhea in Children in Primary Health Care

2020 ◽  
Vol 8 (1) ◽  
pp. 74
Author(s):  
Masta Hutasoit
Keyword(s):  
Health Care ◽  
Primary Health Care ◽  
Zinc Supplementation ◽  
Healing Process ◽  
Oral Rehydration Salt ◽  
The Body ◽  
High Rate ◽  
Oral Rehydration ◽  
Primary Health ◽  
The Relationship

<div class="WordSection1"><p align="center"><strong>ABSTRACT</strong></p><p><strong> </strong></p><p>The high rate of infant morbidity and mortality due to diarrhea is still a focus on children's health. In addition to Oral Rehydration Salt (ORS), zinc is a supplement needed to treat diarrhea. As long as the child has diarrhea, the body will lose zinc, so that additional zinc is needed to accelerate the healing process of diarrhea. Zinc is an important micronutrient in the growth of children and is able to prevent diarrhea 2-3 months after diarrhea. The previous study showed that most mothers do not give zinc to diarrhea children (59.3 %), thus there are still many recurrent diarrhea in children. Objective of study to determine the relationship between zinc supplementation in children with diarrhea and the incidence of recurrent diarrhea at Kasihan Primary Health Care, Bantul. We used descriptive correlational with a retrospective approach. The number of respondents was 47 children under five years (0-59 months) with diarrhea who were taken to primary health care and received zinc therapy. The sampling technique was carried out by purposive sampling. Data collection was performed by filling out the questionnaire by visiting the respondent's house (home visit). The result of the contingency coefficient showed p= 0.013 (p &lt; 0.05) which means that there was a statistically significant relationship between zinc supplementation and the incidence of recurrent diarrhea. The closeness of the relationship between the two variables was indicated by the correlation coefficient value of 0.342 which was in a moderate relationship. There is a correlation between giving zinc supplementation to children with recurrent diarrhea in Primary Health Care</p><p> </p><p><strong><br /></strong></p></div>

Role of FLT3 gene mutations in acute myeloid leukemia: effect on course of disease and results of therapy

2019 ◽  
Vol XIV (1) ◽  
Author(s):  
A.M. Radzhabova ◽  
S.V. Voloshin ◽  
I.S. Martynkevich ◽  
A.A. Kuzyaeva ◽  
V.A. Shuvaev ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Gene Mutations ◽  
Course Of Disease ◽  
Acute Myeloid

Therapeutic Effects of Hab Shabyar on Open-Angle Glaucoma: A Double-Blinded, Randomized, Placebo-Controlled Trial

2019 ◽  
Vol 8 ◽  
pp. 1218
Author(s):  
Ebrahim Khalil BaniHabib ◽  
Ali Mostafai ◽  
Seyyed Mohammad Bagher Fazljou ◽  
Ghadir Mohammdi
Keyword(s):  
Placebo Group ◽  
Intraocular Pressure ◽  
Open Angle Glaucoma ◽  
Controlled Trial ◽  
Intervention Group ◽  
Therapeutic Effects ◽  
Open Angle ◽  
The Mean ◽  
The Right ◽  
Double Blinded

Background: Open-angle glaucoma (OAG) is one of the leading causes of blindness worldwide. This study evaluates the therapeutic effects of hab shabyar in patients with open-angle glaucoma. Materials and Methods: In this clinical randomized controlled trial, 50 patients with OAG were randomized into two groups. The intervention group was received a drop of timolol plus 500 mg of hab shabyar every 12 hours. The placebo group was received a drop of timolol every 12 hours plus 500 mg of wheat germ as a placebo. The intraocular pressure in patients with OAG was measured in each group and compared at before the intervention (t1), one month (t2), and two months (t3) after the intervention. Results: The mean decrease in intraocular pressure for the right eye at three times in the intervention group was statistically significant, but the mean decrease in the placebo group was not significant. Similar results were obtained for the left eye at t1 when compared to t3. The patients in the intervention group expressed more satisfaction than the patients in the placebo group (P≤0.001). Conclusion: Our study demonstrated that consumption of timolol plus hab shabyar instead of consuming of timolol alone was probably more effective for reducing intraocular pressure in patients with OAG.[GMJ.2019;In press:e1218]

scholarly journals AB0676 THE ROLE OF ACPA AND ANA IN SPONDYLOARTHRITIS: HOW THE AUTOIMMUNE DYSREGULATION CAN AFFECT THE COURSE OF DISEASE AND THERAPEUTIC SUCCESS OF MONOTHERAPY DMARDS AND bDMARDs

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1633.1-1633
Author(s):  
D. Cici ◽  
C. Rotondo ◽  
A. Corrado ◽  
S. Berardi ◽  
N. Mansueto ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Start Time ◽  
Disease Manifestation ◽  
Therapeutic Success ◽  
Course Of Disease ◽  
Drug Survival ◽  
Comorbidity Index ◽  
Citrullinated Protein ◽  
Axial Involvement

Background:Occasional findings of anti-citrullinated-protein-antibodies (ACPA) and anti-nuclear-antibodies (ANA) were rarely described in literature on Psoriatic Arthritis (PsA) and on Spondyloarthritis (SpA) in general. How these autoimmune dysregulations can affect the course of them is not yet understood.Objectives:The aim of our study is to evaluate if the presence of ACPA and ANA can determine different disease subsets and influence the DMARDs monotherapy (methotrexate) drug survival (DSM) and b-DMARDs multi-failure patients (MF).Methods:We conducted a retrospective study on patients with Psoriatic Arthritis (PsA) and Spondyloarthritis that fulfilled the ASAS and CASPAR criteria. Patients with diagnosis of connective tissue disease and rheumatoid arthritis and patients ≤ 18 years old were excluded from the study. For each patient, the following variables were considered: age, ACPA, ANA, time between arthritis onset and start of DMARDs (start-time), DSM, switch to b-DMARDs (sw-bDMARDs), arthritis subset (oligoarticular (OA), polyarticular (PA), enthesitis (EA), axial involvement (AI)), number of comorbidities (NC), Charlson Comorbidity Index (CCI).Results:150 patients (55% with PsA and 45% with another SpA) were included in the study. No differences were found in age, ANA rate, ACPA rate, start-time, OA, PA, EA, AI, NC and CCI between the PsA and SpA groups.In the whole group of patients, the ACPA+ subjects(11%) had a significant increase of NC (2.47 ± 1.5 vs 1.6 ± 1.4, p=0.035), a trend to higher CCI, to switch to b-DMARDs, and to be MF compared to those without ACPA. In the same group, the ANA+ patients (12%) showed shorter DSM (233.5 wk ± 45.9 vs 548.0 wk ± 56.8, p=0.362) with similar trend in each subgroup (PsA and SpA).In SpA group, the ACPA+ patients(6,3%) had a trend to shorter DSM (269.0 weeks ± 125vs 603.96 wk± 92.8, p=0.492),to higher sw-bDMARDs, and to be MF, higher NC and CCI compared to those without ACPA. No differences in clinical subset (OA, PA, EA, AI) were observed. In the same group the ANA+ patients had significant higher rate of PA (100% vs 65%, p=0.026) rather than OA (0% vs 35%, p=0.025). No significant differences were found in NC, CCI, MF.In the PsA group, ACPA+ patients showed a trend to develop PA and EA subsets, shorter DSM (187.5 wk ± 48.7 vs 299.6 wk ± 31.4, p=0.415), higher rate to sw-bDMARDs and to be MF. The ANA+ PsA patients had higher trend to develop PA and AI subsets rather than OA and EA. All ANA+ patients were MF (100% vs 42%, p=0.046).Conclusion:The ACPA and ANA positivity in PsA and SpA patients could be suggestive of more severe clinical disease manifestation, higher frequency of comorbidities and lower predicted 10-year survival (CCI). Moreover, this autoimmune dysregulation could be associated with worse drug survival in monotherapy with methotrexate and higher chance to be MF. Therefore, they can be taken into account for clinical management of these patients.Disclosure of Interests:None declared

scholarly journals Neuroprotective Metabolites of Hericium erinaceus Promote Neuro-Healthy Aging

2021 ◽  
Vol 22 (12) ◽  
pp. 6379
Author(s):  
Elisa Roda ◽  
Erica Cecilia Priori ◽  
Daniela Ratto ◽  
Fabrizio De Luca ◽  
Carmine Di Iorio ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Healthy Aging ◽  
Molecular Layer ◽  
Dietary Supplementation ◽  
Purkinje Neurons ◽  
Geriatric Syndrome ◽  
Oral Supplementation ◽  
Erinacine A ◽  
And Oxidative Stress

Frailty is a geriatric syndrome associated with both locomotor and cognitive decline, typically linked to chronic systemic inflammation, i.e., inflammaging. In the current study, we investigated the effect of a two-month oral supplementation with standardized extracts of H. erinaceus, containing a known amount of Erinacine A, Hericenone C, Hericenone D, and L-ergothioneine, on locomotor frailty and cerebellum of aged mice. Locomotor performances were monitored comparing healthy aging and frail mice. Cerebellar volume and cytoarchitecture, together with inflammatory and oxidative stress pathways, were assessed focusing on senescent frail animals. H. erinaceus partially recovered the aged-related decline of locomotor performances. Histopathological analyses paralleled by immunocytochemical evaluation of specific molecules strengthened the neuroprotective role of H. erinaceus able to ameliorate cerebellar alterations, i.e., milder volume reduction, slighter molecular layer thickness decrease and minor percentage of shrunken Purkinje neurons, also diminishing inflammation and oxidative stress in frail mice while increasing a key longevity regulator and a neuroprotective molecule. Thus, our present findings demonstrated the efficacy of a non-pharmacological approach, based on the dietary supplementation using H. erinaceus extract, which represent a promising adjuvant therapy to be associated with conventional geriatric treatments.

Sign in / Sign up

Export Citation Format

Share Document